AXLRx Book a callCommission

Commercial stage 03

Commercial Planning

How do we position, segment and win share?

Commercial Planning report types

1 published Field-Force Strategy How the prescriber base, reimbursement channel and targeting gate should shape field deployment. Account depth vs. reach, channel coverage, and territory design. SFE · Sales Ops · Commercial Planning 43 published Launch Readiness The competitive, epidemiological, and payer-readiness case for entering a market before launch. What a pre-launch asset needs to prove, size, and prepare for. LR · Launch Lead · BD

Every Commercial Planning analysis

SFE · Oncology · Sfe · Commercial Planning US NSCLC Field-Force Strategy NSCLC is a specialist, buy-and-bill oncology market, not a mass-reach primary-care one. A concentrated medical-oncology prescriber base, biomarker-gated prescribing, and infused immuno-oncology under Medicare Part B dictate a small, account-based key-account and MSL field model. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Hereditary Angioedema Launch Readiness Lanadelumab leaves the never-prophylaxed UK HAE population open. This sizes the PAS discount needed to clear NICE's standard TA bar, and the donidalorsen clock a fast-moving competitor is running against you. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Myasthenia Gravis Launch Readiness NICE's terminated eculizumab appraisal for gMG remains the price precedent every new asset must clear. 2,000-3,000 refractory patients have no NICE-commissioned biologic option, and the IVIg-offset economics decide whether a launch is viable. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Bd US Sickle Cell Disease Launch Readiness Two withdrawals opened a 55,000–65,000-patient white space in Sickle Cell Disease — speed, not differentiation, is the binding constraint. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Bd US Dravet Syndrome Launch Readiness The 1,400–2,000-patient refractory Dravet cohort is the opening. REMS-free cardiac safety and a 45%-Medicaid access plan decide who reaches it. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Pompe Disease Launch Readiness An ADA-positive-specific NICE case beats competing on incremental FVC improvement against alglucosidase. The 80-120 NIV-dependent LOPD patients are the highest-urgency target, and the BIMDG partnership shapes NICE's evidence bar. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Fabry Disease Launch Readiness The £144M NHS Fabry market is the largest in Europe, and already has two established agents. An ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Readiness FR PNH Launch Readiness Iptacopan reached French PNH patients through early access, before EU marketing authorisation took effect. HAS granted accès précoce two weeks ahead of it. Any new PNH entrant must be dossier-ready for this track before, not after, EU approval. FR · In-Market · 24–32 pp · PDF · Excel · PPT LR · Pulmonology · Launch Lead · Bd US COPD Launch Readiness Ensifentrine and dupilumab, both approved in 2024, already own the exacerbator add-on tier. A new entrant must clear a 31-41% exacerbation-reduction bar and pick a phenotype-agnostic or eosinophil-gated lane before it competes on anything else. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access US Hereditary Angioedema Launch Readiness Binding constraint: grow the never-prophylaxed cohort before donidalorsen resets the oral efficacy bar — not switch stable lanadelumab patients. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK IgA Nephropathy Launch Readiness NICE will reject any IgAN submission not built on eGFR slope with mandatory SGLT2i background. This sizes the 3,000-5,000 UK patients eligible for a novel agent and the ESRD-delay cost model that clears the QALY bar. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access US PNH Launch Readiness Binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort anti-C5 can't resolve — inside a pricing ceiling iptacopan already set. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Oncology · Launch Readiness US Breast Cancer HR+/HER2- Launch Readiness The post-CDK4/6 line in HR+/HER2- metastatic breast cancer is fragmented by biomarker. Elacestrant's own cost-effectiveness analysis found it 58 times above the standard willingness-to-pay threshold. That precedent is the bar a new targeted entrant must clear. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Pompe Disease Launch Readiness A new-entrant ERT cannot compete on NPHC-covered alglucosidase alone. The constraint is the NPHC step-edit plus Sanofi's entrenched home-infusion relationship at KFSH&RC, which any entrant must replicate from a standing start. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Fabry Disease Launch Readiness Both approved Fabry ERTs are already NPHC-covered in the GCC, so the constraint is finding an unaddressed niche. That means the 30-50 patient ADA-positive cohort, or the HEK-assay bottleneck that locks non-KFSH&RC patients out of oral therapy. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Spinal Muscular Atrophy Launch Readiness The GCC SMA market already has three NPHC-covered agents spanning Types 1-3. A new entrant has exactly two open niches: the Zolgensma-attenuation cohort, or undiagnosed adult-onset Type 4. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Readiness US Gaucher Disease Launch Readiness Five approved Type 1 Gaucher therapies treat the body, not the brain. A genotype gate locks a meaningful share of the highest-prevalence population out of the only oral option, and a Phase 3 gene therapy trial is now racing to close that gap. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access US IgA Nephropathy Launch Readiness Binding constraint: eGFR-confirmed evidence beats a second accelerated approval on UPCR surrogate data alone. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Sickle Cell Disease Launch Readiness GCC SCD is the region's largest rare-disease market at 200,000-250,000 patients, with no novel SFDA-registered therapy. Post-withdrawal, the binding constraint is price, not competition or diagnosis. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access US Myasthenia Gravis Launch Readiness Binding constraint: address FcRn-inadequate responders or claim a serostatus niche — efgartigimod sets both the clinical and ICER pricing bar. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC IgA Nephropathy Launch Readiness No novel IgA nephropathy agent is SFDA-registered in the GCC. First-mover filing, not clinical differentiation, decides which drug becomes the de-facto standard. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Bd US Fabry Disease Launch Readiness The ADA-positive suboptimal-agalsidase-responder niche (200–400 US patients) is Fabry's only clean pre-launch opening. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Neurology · Launch Lead · Bd US Alzheimer's Disease Launch Readiness Two anti-amyloid agents already sit inside CMS's coverage-with-evidence-development registry. A new entrant inherits that gate and must price inside ICER's benchmark to avoid Aduhelm's fate. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC ATTR Amyloidosis Launch Readiness No ATTR-CM treatment is SFDA-registered in the GCC, and the binding constraint is diagnosis, not competition. Without Tc-PYP expansion beyond four centres, a first-mover drug has almost no diagnosed patients to treat. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Spinal Muscular Atrophy Launch Readiness A mature three-drug NICE framework leaves no room for parity entry in UK SMA. The Zolgensma-attenuation and Type 4 adult niches are unserved, and NHS gene therapy centre capacity constrains every new entrant. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Bd US Spinal Muscular Atrophy Launch Readiness A fourth SMA drug has no room in the broad market — the opening is the 500–700-patient Zolgensma-attenuation cohort with no PA pathway yet. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC PNH Launch Readiness First-mover oral complement inhibition in GCC PNH is a closing window. SFDA registration ahead of iptacopan, not competitive differentiation from entrenched anti-C5, decides commercial success. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Metabolic · Launch Lead · Bd US Type 2 Diabetes Launch Readiness Tirzepatide's 41% new-GLP-1 share and semaglutide's SELECT label set the efficacy and label bar. A new entrant must clear both while an IRA-reset price anchor is closing in behind it. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Myasthenia Gravis Launch Readiness Refractory gMG in the GCC is a 200-300 patient market concentrated at fewer than 15 named neurologists. The constraint is building a specialist key-account relationship, not clinical proof. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Immunology · Launch Lead · Bd US Plaque Psoriasis Launch Readiness Bimekizumab already clears PASI 90 in 85% of patients at week 16. A new plaque psoriasis entrant has to win on dosing interval or route, not incremental clearance, against an incumbent price anchor the IRA has already cut 66-67%. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access US ATTR Amyloidosis Launch Readiness Binding constraint: capture newly diagnosed ATTR-CM volume and survive ICER's steepest value gap in the rare-disease basket. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Dravet Syndrome Launch Readiness 600-900 UK Dravet patients remain uncontrolled on CBD plus fenfluramine. This weighs the cardiac-monitoring burden a REMS-free agent could remove against the soticlestat clock competing for the same refractory population. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK ATTR Amyloidosis Launch Readiness Any new ATTR-CM entrant is judged against tafamidis on NICE's TA984 QALY bar, now joined by acoramidis's TA1121 recommendation. The diagnosis pipeline still leaves 15,000-36,000 UK patients undiagnosed, and the National Amyloidosis Centre is the single investment that decides the outcome. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK PNH Launch Readiness Ultomiris cannot resolve the EVH-dominant PNH population, and that gap defines the UK opportunity. Every PNH agent has now cleared the standard NICE Technology Appraisal bar; this sizes the PAS discount required to hit it before MHRA approval. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Oncology · CI Team · Launch Lead US NSCLC Launch Readiness Pembrolizumab holds an estimated 52% of first-line NSCLC on five years of precedent. Payers evaluate every new IO or targeted asset against KEYNOTE, CheckMate and IMpower coverage policy, not against a fresh trial design. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Bd US Pompe Disease Launch Readiness 375–600 US LOPD patients are failing next-gen ERT — ADA superiority and first-line labeling decide who can reach them. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Readiness US Cold Agglutinin Disease Launch Readiness Sutimlimab's CARDINAL trial left 46% of patients without a haemoglobin response. The two most-advanced next-generation complement inhibitors then abandoned cold agglutinin disease after its launch, leaving the entry gap defined by non-response and cost, not a clinical rival. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access UK Sickle Cell Disease Launch Readiness NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent. 4,000-6,000 UK patients sit in a post-withdrawal white space, and the WAC ceiling decides whether you repeat that outcome. UK · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Hereditary Angioedema Launch Readiness HAE prophylaxis barely exists as a category in the GCC. Under 15% of patients are on any prophylaxis versus 35-40% in the US, making this category creation, not competitive share capture. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Lead · Market Access GCC Dravet Syndrome Launch Readiness The binding constraint for a new Dravet agent in the GCC is regulatory classification, not efficacy. Any agent must clear the SFDA Controlled Drug Board as non-controlled, because CBD-class compounds are permanently excluded. GCC · In-Market · 24–32 pp · PDF · Excel · PPT LR · Rare Disease · Launch Readiness DE PNH Launch Readiness Iptacopan already cleared Germany's AMNOG process with a substantial benefit finding and no comparator dossier. A new entrant without orphan-pathway standing has to win that same finding the hard way, through IQWiG. DE · In-Market · 24–32 pp · PDF · Excel · PPT LR · Immunology · Launch Lead · Bd US Atopic Dermatitis Launch Readiness Dupilumab's 70% share sets the biologic entrenchment bar. The 2022 JAK boxed warning sets a second, harder gate for any oral entrant. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Metabolic · Launch Lead · Market Access US Obesity Launch Readiness Wegovy and Zepbound already occupy the injectable position. A new entrant must clear the 20.9% efficacy bar and price beneath the $274 IRA reset arriving in 2027. US · In-Market · 24–32 pp · PDF · Excel · PPT LR · Metabolic · Launch Lead · Bd US MASH Launch Readiness Rezdiffra and Wegovy already hold the noncirrhotic F2-F3 label. The clearer opening for a new entrant is the compensated-cirrhosis boundary neither drug covers. US · In-Market · 24–32 pp · PDF · Excel · PPT

Other stages

01 · Market Intelligence02 · Sizing & Access04 · Analytics & Operations